The estimated Net Worth of Dimitrios Chondros is at least $2.31 Milión dollars as of 3 August 2019. Dimitrios Chondros owns over 1,328 units of Halozyme Therapeutics stock worth over $2,291,504 and over the last 6 years Dimitrios sold HALO stock worth over $22,178.
Dimitrios has made over 5 trades of the Halozyme Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Dimitrios sold 1,328 units of HALO stock worth $22,178 on 3 August 2019.
The largest trade Dimitrios's ever made was exercising 6,790 units of Halozyme Therapeutics stock on 14 February 2019 worth over $403,258. On average, Dimitrios trades about 2,011 units every 54 days since 2018. As of 3 August 2019 Dimitrios still owns at least 38,584 units of Halozyme Therapeutics stock.
You can see the complete history of Dimitrios Chondros stock trades at the bottom of the page.
Dimitrios's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121.
Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay a Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: